Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CARsgen Therapeutics Holdings Ltd. (CRTHF) AI Stock Analysis

Top Page

CRTHF

CARsgen Therapeutics Holdings Ltd.

(Other OTC:CRTHF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and Gross Profit GrowthThe sharp 2025 revenue increase, together with a positive gross profit, indicates improving commercial traction and product economics. If sustained, this expanding revenue base can provide greater operating leverage and gradually improve the company’s ability to fund its development platform.
Negative Factors
Persistent Operating LossesLarge operating and net losses show that the business has not yet converted improving revenue into sustainable profitability. Continued losses can consume capital, constrain investment choices, and leave future earnings dependent on successful product development or additional funding.

CARsgen Therapeutics Holdings Ltd. (CRTHF) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%CRTHF+167.77%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$6.32B
Dividend Yield
―
Average Volume (3M)
2,333
Price to Earnings (P/E)
-56.1
Beta (1Y)
0.49
Revenue Growth
67.68%
EPS Growth
81.91%
Country
US
Employees
424
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. Business Overview & Revenue Model

Company Description

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts ar...

CARsgen Therapeutics Holdings Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CRTHF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:9966HK:996652NeutralHKD 6.06B-30.68-10.27%―-31.77%-177.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2126HK:212649NeutralHKD 925.48M-2.35-66.16%―67.48%43.84%
HK:2616HK:261647NeutralHKD 7.77B-15.53-43.54%―116.67%-0.42%
HK:9688HK:968846NeutralHKD 21.69B-12.70-27.40%―5.38%16.86%
HK:1877HK:187741NeutralHKD 30.07B-69.15-7.23%―35.82%54.40%

* Healthcare Sector Average

Performance Comparison

0%100%200%CRTHFHK:9688HK:9966HK:1877HK:2126HK:2616Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
CRTHF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRTHFCARsgen Therapeutics Holdings Ltd.1.621.02167.77%
HK:9688Zai Lab Ltd17.37-3.65-17.36%
HK:9966Alphamab Oncology6.21-5.46-46.79%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H15.26-11.44-42.85%
HK:2126JW (Cayman) Therapeutics Co. Ltd.2.22-1.82-45.05%
HK:2616CStone Pharmaceuticals4.94-1.28-20.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.